Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820347 | 0.91 | NOTUM (0.48) | MAPTNOTUMHTTLMNAALDH1A1 | |
| SCHEMBL26763820 | 0.83 | NOTUM (0.58) | MAPTNOTUMKMT2AMEN1NPSR1 | |
| SCHEMBL2611041 | 0.78 | NOTUM (0.65) | NOTUM | |
| SCHEMBL12308329 | 0.76 | NOTUM (0.69) | MAPTNOTUMKMT2AMEN1NPSR1 | |
| SCHEMBL16019534 | 0.75 | TNKS (0.41) | MAPTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL19755626 | 0.74 | C5AR1 (0.35) | KMT2AMEN1LMNAHPGDTSHR | |
| SCHEMBL19046968 | 0.74 | C5AR1 (0.35) | KMT2AMEN1LMNAHPGDTSHR | |
| SCHEMBL16219037 | 0.72 | ALDH1A1 (0.48) | MAPTNOTUMKMT2AMEN1NPSR1 | |
| SCHEMBL23316487 | 0.72 | C5AR1 (0.36) | MAPTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL17368392 | 0.71 | KMT2A (0.55) | MAPTNOTUMKMT2AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | MAPT 3976/4885NOTUM 3656/4885KMT2A 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.